GlassScriptPhysician profile
James L Fanelli
NPI 1023144383
$38,796.42
in general payments reported to CMS, 2019-2025
20 companies · $4,552 in 2025
The $4,552 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,596 · 2020: $737 · 2021: $1,587 · 2022: $302 · 2023: $11K · 2024: $17K · 2025: $4,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Travel and Lodging: $6,406 · Food and Beverage: $1,364 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,000.00 |
| Travel and Lodging | $6,405.90 |
| Food and Beverage | $1,363.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $805.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $26,957.96 | 2021-2024 | |
| Heidelberg Engineering, INC. | $6,433.84 | 2019-2025 | Spectralis |
| Maculogix, INC. | $3,098.30 | 2019-2021 | |
| Glaukos Corporation | $1,138.09 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $493.80 | 2022-2025 | Cequa |
| Dompe US, INC. | $212.52 | 2020-2024 | Oxervate |
| Bausch & Lomb Americas INC. | $78.33 | 2022-2024 | Xiidra, Vyzulta, Miebo |
| Carl Zeiss Meditec USA, INC. | $65.04 | 2024 | Cirrus Hd-Oct |
| Oyster Point Pharma, INC. | $40.45 | 2022-2023 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $34.59 | 2022 | |
| Kala Pharmaceuticals, INC. | $33.45 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $32.18 | 2019-2020 | |
| Biotissue Holdings INC. | $29.66 | 2022-2024 | |
| Johnson & Johnson Vision Care, INC. | $24.37 | 2020-2022 | |
| Abbvie INC. | $24.07 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $23.48 | 2019 | |
| Topcon Healthcare Solutions, INC. | $22.68 | 2019 | |
| Thea Pharma INC. | $19.41 | 2023 | |
| Eyevance Pharmaceuticals LLC | $17.51 | 2022 | |
| Allergan, INC. | $16.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fanelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.